hydralazine has been researched along with Albuminuria in 33 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Obesity increased albuminuria and glomerulosclerosis, which were significantly ameliorated by low-dose hydralazine in the absence of a blood pressure-lowering effect." | 8.12 | Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease. ( Chen, H; Chen, J; Faiz, A; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2022) |
| "Gestational hydralazine reduced renal global DNA methylation in offspring of obese mothers and attenuated maternal obesity-induced renal fibrosis." | 8.02 | Low-dose hydralazine during gestation reduces renal fibrosis in rodent offspring exposed to maternal high fat diet. ( Chen, H; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2021) |
| "Studies were performed to determine if early treatment with an angiotensin II (Ang II) receptor blocker (ARB), olmesartan, prevents the onset of microalbuminuria by attenuating glomerular podocyte injury in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with type 2 diabetes mellitus." | 7.78 | Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. ( Hara, T; Hayden, MR; Hitomi, H; Ichimura, A; Ito, S; Kaifu, K; Kawachi, H; Kiyomoto, H; Kobori, H; Kohno, M; Matsumoto, S; Nishijima, Y; Nishiyama, A; Ohsaki, H; Sofue, T; Sowers, JR; Urushihara, M; Whaley-Connell, A, 2012) |
| "The ability of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor simvastatin to reverse established cardiovascular and renal alterations and oxidative stress was assessed in angiotensin II (AngII) hypertension." | 7.74 | Simvastatin reverses target organ damage and oxidative stress in Angiotensin II hypertension: comparison with apocynin, tempol, and hydralazine. ( Delbosc, S; Jover, B; Mimran, A; Rugale, C, 2007) |
| " We tested the hypothesis that endothelin (ET)(A/B) receptor blockade with bosentan (100 mg/kg by gavage after age 4 weeks) ameliorates cardiac and renal damage by decreasing inflammation in rats harboring both human renin and angiotensinogen genes (dTGR)." | 7.70 | Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. ( Breu, V; Dechend, R; Ganten, D; Genersch, E; Haller, H; Löffler, BM; Luft, FC; Mervaala, EM; Muller, DN; Park, JK; Schmidt, F; Schneider, W, 2000) |
| "We compared the effects of the angiotensin-converting enzyme inhibitor enalapril and a conventional antihypertensive regimen (hydralazine and metoprolol) on kidney function, albuminuria, and glomerular ultrastructure in hypertensive diabetic and nondiabetic rats." | 7.68 | Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy. ( Allen, TJ; Clarke, BE; Cooper, ME; Doyle, AE; Jerums, G; O'Brien, RC; Papazoglou, D, 1990) |
| " Obesity increased albuminuria and glomerulosclerosis, which were significantly ameliorated by low-dose hydralazine in the absence of a blood pressure-lowering effect." | 4.12 | Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease. ( Chen, H; Chen, J; Faiz, A; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2022) |
| "Gestational hydralazine reduced renal global DNA methylation in offspring of obese mothers and attenuated maternal obesity-induced renal fibrosis." | 4.02 | Low-dose hydralazine during gestation reduces renal fibrosis in rodent offspring exposed to maternal high fat diet. ( Chen, H; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2021) |
| "Studies were performed to determine if early treatment with an angiotensin II (Ang II) receptor blocker (ARB), olmesartan, prevents the onset of microalbuminuria by attenuating glomerular podocyte injury in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with type 2 diabetes mellitus." | 3.78 | Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. ( Hara, T; Hayden, MR; Hitomi, H; Ichimura, A; Ito, S; Kaifu, K; Kawachi, H; Kiyomoto, H; Kobori, H; Kohno, M; Matsumoto, S; Nishijima, Y; Nishiyama, A; Ohsaki, H; Sofue, T; Sowers, JR; Urushihara, M; Whaley-Connell, A, 2012) |
| "The ability of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor simvastatin to reverse established cardiovascular and renal alterations and oxidative stress was assessed in angiotensin II (AngII) hypertension." | 3.74 | Simvastatin reverses target organ damage and oxidative stress in Angiotensin II hypertension: comparison with apocynin, tempol, and hydralazine. ( Delbosc, S; Jover, B; Mimran, A; Rugale, C, 2007) |
| " We have previously reported that mice overexpressing angiotensinogen in renal proximal tubular cells (RPTC) develop hypertension, albuminuria, and renal injury." | 3.74 | Overexpression of angiotensinogen increases tubular apoptosis in diabetes. ( Brezniceanu, ML; Chan, JS; Chénier, I; Filep, JG; Ingelfinger, JR; Liu, F; Sachetelli, S; Wei, CC; Zhang, SL, 2008) |
| " We tested the hypothesis that endothelin (ET)(A/B) receptor blockade with bosentan (100 mg/kg by gavage after age 4 weeks) ameliorates cardiac and renal damage by decreasing inflammation in rats harboring both human renin and angiotensinogen genes (dTGR)." | 3.70 | Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. ( Breu, V; Dechend, R; Ganten, D; Genersch, E; Haller, H; Löffler, BM; Luft, FC; Mervaala, EM; Muller, DN; Park, JK; Schmidt, F; Schneider, W, 2000) |
| "We have compared the effects of the angiotensin converting enzyme inhibitor, perindopril, and a conventional antihypertensive regimen (triple therapy: hydralazine, reserpine and hydrochlorothiazide) on kidney function and albuminuria in hypertensive diabetic rats." | 3.68 | Antihypertensive therapy in a model combining spontaneous hypertension with diabetes. ( Allen, TJ; Cooper, ME; Doyle, AE; Jerums, G; O'Brien, RC; Rumble, JR, 1992) |
| "To evaluate the role of glomerular hypertension, glomerular hypertrophy, glomerular lipid deposition, and plasma cholesterol levels in diabetic glomerulopathy, Munich-Wistar rats received streptozocin and daily insulin injections and were assigned to one of three groups: untreated diabetic (DMC), hydralazine-treated diabetic (DMH), and enalapril-treated diabetic (DME)." | 3.68 | Glomerular abnormalities in long-term experimental diabetes. Role of hemodynamic and nonhemodynamic factors and effects of antihypertensive therapy. ( Fujihara, CK; Padilha, RM; Zatz, R, 1992) |
| "We compared the effects of the angiotensin-converting enzyme inhibitor enalapril and a conventional antihypertensive regimen (hydralazine and metoprolol) on kidney function, albuminuria, and glomerular ultrastructure in hypertensive diabetic and nondiabetic rats." | 3.68 | Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy. ( Allen, TJ; Clarke, BE; Cooper, ME; Doyle, AE; Jerums, G; O'Brien, RC; Papazoglou, D, 1990) |
| "Aliskiren treatment almost completely suppressed angiotensin I and resulted in lower angiotensin II concentration than ramipril treatment." | 1.40 | Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading. ( Ayuzawa, N; Fujita, T; Ishizawa, K; Kawarazaki, W; Nagase, M; Takeuchi, M; Ueda, K; Yoshida, S, 2014) |
| "Treatment with candesartan, but not hydralazine, reduced these values to levels in db/m mice." | 1.35 | Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy. ( Hashimoto, T; Hirawa, N; Imai, N; Ishigami, T; Kihara, M; Kitamura, H; Kiuchi, Y; Nomura, K; Tamura, K; Toya, Y; Umemura, S; Yasuzaki, H; Yoshida, S, 2009) |
| "Perindopril was associated with significantly lower AER than lacidipine, whereas lacidipine was more potent in preventing increases in ocular AVC." | 1.29 | Organ specificity of antihypertensive therapy on ocular albumin vascular clearance and albuminuria in the hypertensive diabetic rat. ( Cooper, M; Gin, T; Jerums, G; Joon, TL; Panagiotopoulos, S; Taylor, H, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (15.15) | 18.7374 |
| 1990's | 13 (39.39) | 18.2507 |
| 2000's | 10 (30.30) | 29.6817 |
| 2010's | 3 (9.09) | 24.3611 |
| 2020's | 2 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Larkin, BP | 2 |
| Nguyen, LT | 2 |
| Hou, M | 2 |
| Glastras, SJ | 2 |
| Chen, H | 2 |
| Faiz, A | 1 |
| Chen, J | 1 |
| Wang, R | 2 |
| Pollock, CA | 2 |
| Saad, S | 2 |
| Yoshida, S | 2 |
| Ishizawa, K | 1 |
| Ayuzawa, N | 1 |
| Ueda, K | 1 |
| Takeuchi, M | 1 |
| Kawarazaki, W | 1 |
| Fujita, T | 1 |
| Nagase, M | 1 |
| Hashimoto, T | 1 |
| Kihara, M | 1 |
| Imai, N | 1 |
| Yasuzaki, H | 1 |
| Nomura, K | 1 |
| Kiuchi, Y | 1 |
| Tamura, K | 1 |
| Ishigami, T | 1 |
| Hirawa, N | 1 |
| Toya, Y | 1 |
| Kitamura, H | 1 |
| Umemura, S | 1 |
| Leelahavanichkul, A | 1 |
| Yan, Q | 1 |
| Hu, X | 1 |
| Eisner, C | 1 |
| Huang, Y | 1 |
| Chen, R | 1 |
| Mizel, D | 1 |
| Zhou, H | 1 |
| Wright, EC | 1 |
| Kopp, JB | 1 |
| Schnermann, J | 1 |
| Yuen, PS | 1 |
| Star, RA | 1 |
| Sofue, T | 1 |
| Kiyomoto, H | 1 |
| Kobori, H | 1 |
| Urushihara, M | 1 |
| Nishijima, Y | 1 |
| Kaifu, K | 1 |
| Hara, T | 1 |
| Matsumoto, S | 1 |
| Ichimura, A | 1 |
| Ohsaki, H | 1 |
| Hitomi, H | 1 |
| Kawachi, H | 1 |
| Hayden, MR | 1 |
| Whaley-Connell, A | 1 |
| Sowers, JR | 1 |
| Ito, S | 1 |
| Kohno, M | 1 |
| Nishiyama, A | 1 |
| Baumann, M | 1 |
| Janssen, BJ | 1 |
| Hermans, JJ | 1 |
| Peutz-Kootstra, C | 1 |
| Witzke, O | 1 |
| Smits, JF | 1 |
| Struijker Boudier, HA | 1 |
| Rugale, C | 1 |
| Delbosc, S | 1 |
| Mimran, A | 1 |
| Jover, B | 2 |
| Liu, F | 1 |
| Brezniceanu, ML | 1 |
| Wei, CC | 1 |
| Chénier, I | 1 |
| Sachetelli, S | 1 |
| Zhang, SL | 1 |
| Filep, JG | 1 |
| Ingelfinger, JR | 1 |
| Chan, JS | 1 |
| Odum, J | 1 |
| Purkiss, J | 1 |
| Naish, PF | 1 |
| Huijberts, M | 1 |
| Wolffenbuttel, B | 1 |
| Crijns, F | 1 |
| Kruseman, AN | 1 |
| Bemelmans, M | 1 |
| Van Essen, H | 1 |
| Smits, J | 1 |
| Boudier, HS | 1 |
| Ljungman, S | 2 |
| Wikstrand, J | 2 |
| Hartford, M | 2 |
| Aurell, M | 1 |
| Lindstedt, G | 1 |
| Berglund, G | 1 |
| Kohara, K | 1 |
| Mikami, H | 1 |
| Okuda, N | 1 |
| Higaki, J | 1 |
| Ogihara, T | 1 |
| Gin, T | 1 |
| Joon, TL | 1 |
| Panagiotopoulos, S | 1 |
| Cooper, M | 1 |
| Taylor, H | 1 |
| Jerums, G | 3 |
| Siewert-Delle, A | 1 |
| Yamamoto, M | 1 |
| Fukui, M | 1 |
| Shou, I | 1 |
| Wang, LN | 1 |
| Sekizuka, K | 1 |
| Suzuki, S | 1 |
| Shirato, I | 1 |
| Tomino, Y | 1 |
| Kai, T | 1 |
| Kino, H | 1 |
| Ishikawa, K | 1 |
| Casellas, D | 1 |
| Benahmed, S | 1 |
| Artuso, A | 1 |
| Mervaala, E | 1 |
| Müller, DN | 2 |
| Schmidt, F | 2 |
| Park, JK | 2 |
| Gross, V | 1 |
| Bader, M | 1 |
| Breu, V | 2 |
| Ganten, D | 2 |
| Haller, H | 2 |
| Luft, FC | 2 |
| Sabbatini, M | 1 |
| Leonardi, A | 1 |
| Testa, R | 1 |
| Vitaioli, L | 1 |
| Amenta, F | 1 |
| Mervaala, EM | 1 |
| Dechend, R | 1 |
| Genersch, E | 1 |
| Löffler, BM | 1 |
| Schneider, W | 1 |
| Obata, J | 1 |
| Nakamura, T | 1 |
| Takano, H | 1 |
| Naito, A | 1 |
| Kimura, H | 1 |
| Yoshida, Y | 1 |
| Shimizu, F | 1 |
| Guo, DF | 1 |
| Inagami, T | 1 |
| Koenen, C | 1 |
| Lang, C | 1 |
| Kempe, HP | 1 |
| Werle, E | 1 |
| Hasslacher, C | 1 |
| Suganami, T | 1 |
| Mukoyama, M | 1 |
| Sugawara, A | 1 |
| Mori, K | 1 |
| Nagae, T | 1 |
| Kasahara, M | 1 |
| Yahata, K | 1 |
| Makino, H | 1 |
| Fujinaga, Y | 1 |
| Ogawa, Y | 1 |
| Tanaka, I | 1 |
| Nakao, K | 1 |
| Pedersen, EB | 1 |
| Mogensen, CE | 2 |
| Teschner, M | 1 |
| Schaefer, RM | 1 |
| Bahner, U | 1 |
| Heidland, A | 1 |
| Cooper, ME | 2 |
| Rumble, JR | 1 |
| Allen, TJ | 2 |
| O'Brien, RC | 2 |
| Doyle, AE | 2 |
| Fujihara, CK | 1 |
| Padilha, RM | 1 |
| Zatz, R | 1 |
| Papazoglou, D | 1 |
| Clarke, BE | 1 |
| Baba, T | 1 |
| Sawicki, PT | 1 |
| Mathiesen, ER | 1 |
| Parving, HH | 1 |
| Hommel, E | 1 |
| Hutchinson, FN | 1 |
| Schambelan, M | 1 |
| Kaysen, GA | 1 |
1 review available for hydralazine and Albuminuria
| Article | Year |
|---|---|
[Nephropathy in type 1 diabetes mellitus. Current experimental and clinical aspects].
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Experimental; Dia | 1992 |
32 other studies available for hydralazine and Albuminuria
| Article | Year |
|---|---|
Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease.
Topics: Albuminuria; Animals; Diet, High-Fat; Disease Models, Animal; Fibrosis; Hydralazine; Inflammation; K | 2022 |
Low-dose hydralazine during gestation reduces renal fibrosis in rodent offspring exposed to maternal high fat diet.
Topics: Albuminuria; Animals; Biomarkers; Body Weight; Collagen; Diet, High-Fat; DNA Methylation; Female; Fi | 2021 |
Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.
Topics: Albuminuria; Amides; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Angiot | 2014 |
Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihype | 2009 |
Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model.
Topics: Albuminuria; Anemia; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertens | 2010 |
Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Glucos | 2012 |
Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age.
Topics: Age Factors; Aging; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; C | 2007 |
Simvastatin reverses target organ damage and oxidative stress in Angiotensin II hypertension: comparison with apocynin, tempol, and hydralazine.
Topics: Acetophenones; Albuminuria; Angiotensin II; Animals; Antihypertensive Agents; Antioxidants; Cardiome | 2007 |
Overexpression of angiotensinogen increases tubular apoptosis in diabetes.
Topics: Albuminuria; Angiotensinogen; Animals; Antihypertensive Agents; Apoptosis; bcl-2-Associated X Protei | 2008 |
Influence of differing classes of antihypertensive agents on mesangial kinetics following partial renal ablation in rats.
Topics: Albuminuria; Animals; Antihypertensive Agents; Biological Transport, Active; Enalapril; Glomerular M | 1994 |
Inhibition of angiotensin-converting enzyme reduces urinary albumin excretion but not regional albumin clearance in experimental diabetes.
Topics: Albumins; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; B | 1993 |
Effects of long-term antihypertensive treatment and aging on renal function and albumin excretion in primary hypertension.
Topics: Aging; Albuminuria; Case-Control Studies; Drug Therapy, Combination; Follow-Up Studies; Glomerular F | 1993 |
Angiotensin blockade and the progression of renal damage in the spontaneously hypertensive rat.
Topics: Albuminuria; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzi | 1993 |
Organ specificity of antihypertensive therapy on ocular albumin vascular clearance and albuminuria in the hypertensive diabetic rat.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Press | 1996 |
Effect of 14 years of antihypertensive treatment on renal function and urinary albumin excretion in primary hypertension.
Topics: Adrenergic beta-Antagonists; Albuminuria; Antihypertensive Agents; Benzothiadiazines; Blood Pressure | 1996 |
Effects of treatment with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor antagonist (AIIRA) on renal function and glomerular injury in subtotal nephrectomized rats.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Bl | 1997 |
Role of the renin-angiotensin system in cardiac hypertrophy and renal glomerular sclerosis in transgenic hypertensive mice carrying both human renin and angiotensinogen genes.
Topics: Albuminuria; Angiotensinogen; Animals; Blood Pressure; Cardiomegaly; Drinking; Fibronectins; Gene Ex | 1998 |
Candesartan and progression of preglomerular lesions in N(G)-nitro-L-arginine methyl ester hypertensive rats.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Bip | 1999 |
Blood pressure-independent effects in rats with human renin and angiotensinogen genes.
Topics: Albuminuria; Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified; Antihypertensi | 2000 |
Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats.
Topics: Albuminuria; Animals; Arterioles; Calcium; Calcium Channel Blockers; Dihydropyridines; Hydralazine; | 2000 |
Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage.
Topics: Albuminuria; Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified; Antihypertensi | 2000 |
Increased gene expression of components of the renin-angiotensin system in glomeruli of genetically hypertensive rats.
Topics: Albuminuria; Angiotensin II; Angiotensinogen; Animals; Antihypertensive Agents; Benzimidazoles; Biph | 2000 |
The influence of the ACE inhibitor lisinopril on the glomerular metabolism of proteolytic enzymes in diabetic rats.
Topics: Acetylglucosaminidase; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressur | 2000 |
Overexpression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury.
Topics: Albuminuria; Animals; Antihypertensive Agents; Blood Pressure; Chemokine CCL2; Complement C3; Glomer | 2001 |
Effect of antihypertensive treatment on urinary albumin excretion, glomerular filtration rate, and renal plasma flow in patients with essential hypertension.
Topics: Aged; Albuminuria; Alprenolol; Animals; Blood Pressure; Female; Glomerular Filtration Rate; Guinea P | 1976 |
Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment.
Topics: Adolescent; Adult; Albuminuria; Diabetic Nephropathies; Furosemide; Glomerular Filtration Rate; Huma | 1976 |
Antihypertensive therapy in a model combining spontaneous hypertension with diabetes.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Gluco | 1992 |
Glomerular abnormalities in long-term experimental diabetes. Role of hemodynamic and nonhemodynamic factors and effects of antihypertensive therapy.
Topics: Albuminuria; Analysis of Variance; Animals; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; | 1992 |
Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy.
Topics: Administration, Oral; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Melli | 1990 |
Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat: are these effects specific for enalapril?
Topics: Albuminuria; Animals; Basement Membrane; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic N | 1989 |
Converting enzyme-inhibition in diabetic nephropathy.
Topics: Albuminuria; Blood Pressure; Captopril; Diabetic Nephropathies; Drug Therapy, Combination; Furosemid | 1989 |
Modulation of albuminuria by dietary protein and converting enzyme inhibition.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Dietary Proteins; Enalapril; Hydrala | 1987 |